FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With ...(ey're taking NovoSeven(R) may be at incr...),Health

Date:5/13/2008

ey're taking NovoSeven(R) may be at increased risk for thrombosis. Serious adverse events which may or may not have been related to the use of NovoSeven(R) occurred in 14 of the 298 patients in the initial clinical program. There have been no reports of NovoSeven(R) causing bad reactions to "analgesics" (such as pain killers), "antibiotics" (the drugs used to treat infection), or "sedatives" (sleeping pills or tranquilizers). Development of antibodies against Factor VII has been reported in Factor VII-deficient patients after treatment with NovoSeven(R). These patients had previously been treated with human plasma and/or plasma-derived Factor VII.

About Novo Nordisk

Novo Nordisk is a health care company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone replacement therapy.

Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Media

Sean Clements

Novo Nordisk

PH: (609) 514-8316

'/>"/>

SOURCE Novo Nordisk Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
2. FDA Approves Health Claim for Brown Rice
3. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
4. FDA approves HeartMate II mechanical heart pump for heart-failure patients
5. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
6. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
9. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
10. VeriPrime Approves New Best Practices for Beef Production
11. U.S. EPA Approves Registration of Antimicrobial Copper Alloys